{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:13:12Z","timestamp":1769188392459,"version":"3.49.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10238-014-0328-z","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T11:26:31Z","timestamp":1417433191000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Beh\u00e7et syndrome: from pathogenesis to novel therapies"],"prefix":"10.1007","volume":"16","author":[{"given":"Gianluigi","family":"Mazzoccoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Matarangolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"De Cata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,2]]},"reference":[{"key":"328_CR1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2014.01.014","volume":"48\u201349","author":"H Yazici","year":"2014","unstructured":"Yazici H, Yazici Y. Criteria for Beh\u00e7et\u2019s disease with reflections on all disease criteria. J Autoimmun. 2014;48\u201349:104\u20137. doi: 10.1016\/j.jaut.2014.01.014 .","journal-title":"J Autoimmun"},{"issue":"6","key":"328_CR2","first-page":"483","volume":"150","author":"T Lehner","year":"1999","unstructured":"Lehner T. Immunopathogenesis of Behcet\u2019s disease. Ann Med Interne (Paris). 1999;150(6):483\u20137.","journal-title":"Ann Med Interne (Paris)"},{"issue":"2","key":"328_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrrheum.2012.156","volume":"9","author":"NL Ambrose","year":"2013","unstructured":"Ambrose NL, Haskard DO. Differential diagnosis and management of Beh\u00e7et syndrome. Nat Rev Rheumatol. 2013;9(2):79\u201389.","journal-title":"Nat Rev Rheumatol"},{"key":"328_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)01137-2","volume":"37","author":"JC Chambers","year":"2000","unstructured":"Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanism in patients with Behcet\u2019s syndrome. J Am Coll Cardiol. 2000;37:517\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"328_CR5","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/rheumatology\/keq090","volume":"49","author":"P Mehta","year":"2010","unstructured":"Mehta P, Laffan M, Haskard DO. Thrombosis and Beh\u00e7et\u2019s syndrome in non-endemic regions. Rheumatology (Oxford). 2010;49(11):2003\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"328_CR6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11926-010-0132-z","volume":"12","author":"Y Yazici","year":"2010","unstructured":"Yazici Y, Yazici H. Behcet\u2019s syndrome. Curr Rheumatol Rep. 2010;12(6):429\u201335.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"328_CR7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International","year":"2014","unstructured":"International Team for the Revision of the International. Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD). The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"328_CR8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/14397595.2013.844400","volume":"24","author":"ST Faezi","year":"2014","unstructured":"Faezi ST, Paragomi P, Shahram F, et al. Clinical features of Behcet\u2019s disease in patients without oral aphthosis. Mod Rheumatol. 2014;24(4):637\u20139.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"328_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/33.2.115","volume":"33","author":"TW O\u2019Neill","year":"1994","unstructured":"O\u2019Neill TW, Rigby AS, Silman AJ, Barnes C. Validation of the International Study Group criteria for Beh\u00e7et\u2019s disease. Br J Rheumatol. 1994;33(2):115\u20137.","journal-title":"Br J Rheumatol"},{"key":"328_CR10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.24423","volume":"61","author":"KT Calamia","year":"2009","unstructured":"Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Beh\u00e7et\u2019s disease in the US: a population-based study. Arthritis Rheum. 2009;61:600\u20134.","journal-title":"Arthritis Rheum"},{"key":"328_CR11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","volume":"60","author":"H Direskeneli","year":"2001","unstructured":"Direskeneli H. Beh\u00e7et\u2019s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996\u20131002.","journal-title":"Ann Rheum Dis"},{"key":"328_CR12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/1529-0131(200101)44:1<239::AID-ANR31>3.0.CO;2-X","volume":"44","author":"A G\u00fcl","year":"2001","unstructured":"G\u00fcl A, Hajeer AH, Worthington J, Barrett JH, Ollier WE, Silman AJ. Evidence for linkage of the HLA-B locus in Beh\u00e7et\u2019s disease, obtained using the transmission disequilibrium test. Arthritis Rheum. 2001;44:239\u201340.","journal-title":"Arthritis Rheum"},{"key":"328_CR13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.24642","volume":"61","author":"M Menthon de","year":"2009","unstructured":"de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51\/B5 and the risk of Beh\u00e7et\u2019s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287\u201396.","journal-title":"Arthritis Rheum"},{"key":"328_CR14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.50.6.351","volume":"50","author":"N Arber","year":"1991","unstructured":"Arber N, Klein T, Meiner Z, Pras E, Weinberger A. Close association of HLA-B51 and B52 in Israeli patients with Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 1991;50:351\u20133.","journal-title":"Ann Rheum Dis"},{"key":"328_CR15","first-page":"1867","volume":"28","author":"C Salvarani","year":"2001","unstructured":"Salvarani C, Boiardi L, Mantovani V, et al. Association of MICA alleles and HLA-B51 in Italian patients with Beh\u00e7et\u2019s disease. J Rheumatol. 2001;28:1867\u201370.","journal-title":"J Rheumatol"},{"key":"328_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1034\/j.1399-0039.2001.580304.x","volume":"58","author":"I K\u00f6tter","year":"2001","unstructured":"K\u00f6tter I, G\u00fcnaydin I, St\u00fcbiger N, et al. Comparative analysis of the association of HLA-B*51 suballeles with Beh\u00e7et\u2019s disease in patients of German and Turkish origin. Tissue Antigens. 2001;58:166\u201370.","journal-title":"Tissue Antigens"},{"key":"328_CR17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/art.10815","volume":"48","author":"T Ahmad","year":"2003","unstructured":"Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Beh\u00e7et\u2019s disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003;48:807\u201313.","journal-title":"Arthritis Rheum"},{"key":"328_CR18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2230.2006.02330.x","volume":"32","author":"EB Baskan","year":"2007","unstructured":"Baskan EB, Yilmaz E, Saricaoglu H, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Beh\u00e7et\u2019s disease. Clin Exp Dermatol. 2007;32:186\u201390.","journal-title":"Clin Exp Dermatol"},{"key":"328_CR19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10384-007-0473-y","volume":"51","author":"N Mizuki","year":"2007","unstructured":"Mizuki N, Meguro A, Tohnai I, G\u00fcl A, Ohno S, Mizuki N. Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Beh\u00e7et\u2019s disease in Turkey. Jpn J Ophthalmol. 2007;51:431\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"328_CR20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/0-306-48382-3_46","volume":"528","author":"NA Ermakova","year":"2003","unstructured":"Ermakova NA, Alekberova ZS, Prokaeva TB, Poljanskaja IB. Frequency of HLA in patients with Beh\u00e7et\u2019s disease and association with occlusive retinal vasculitis. Adv Exp Med Biol. 2003;528:231\u20133.","journal-title":"Adv Exp Med Biol"},{"key":"328_CR21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1034\/j.1399-0039.2003.610110.x","volume":"61","author":"F Choukri","year":"2003","unstructured":"Choukri F, Chakib A, Himmich H, Marih L, Caillat-Zucman S. HLA-B phenotype modifies the course of Beh\u00e7et\u2019s disease in Moroccan patients. Tissue Antigens. 2003;61:92\u20136.","journal-title":"Tissue Antigens"},{"key":"328_CR22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/rheumatology\/40.6.668","volume":"40","author":"A G\u00fcl","year":"2001","unstructured":"G\u00fcl A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Beh\u00e7et\u2019s disease. Rheumatology (Oxford). 2001;40:668\u201372.","journal-title":"Rheumatology (Oxford)"},{"key":"328_CR23","first-page":"391","volume":"1","author":"T Akpolat","year":"1992","unstructured":"Akpolat T, Ko\u00e7 Y, Yeniay I, et al. Familial Beh\u00e7et\u2019s disease. Eur J Med. 1992;1:391\u20135.","journal-title":"Eur J Med"},{"key":"328_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-3476(99)70333-1","volume":"135","author":"I Kon\u00e9-Paut","year":"1999","unstructured":"Kon\u00e9-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Beh\u00e7et\u2019s disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135:89\u201393.","journal-title":"J Pediatr"},{"key":"328_CR25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-3083.1996.d01-53.x","volume":"43","author":"H Direskeneli","year":"1996","unstructured":"Direskeneli H, Hasan A, Shinnick T, et al. Recognition of B-cell epitopes of the 65\u00a0kDa HSP in Beh\u00e7et\u2019s disease. Scand J Immunol. 1996;43:464\u201371.","journal-title":"Scand J Immunol"},{"key":"328_CR26","first-page":"588","volume":"19","author":"Y Suzuki","year":"1992","unstructured":"Suzuki Y, Hoshi K, Matsuda T, Mizushima Y. Increased peripheral blood gamma delta\u00a0+\u00a0T cells and natural killer cells in Beh\u00e7et\u2019s disease. J Rheumatol. 1992;19:588\u201392.","journal-title":"J Rheumatol"},{"key":"328_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1076\/ocii.9.2.85.3973","volume":"9","author":"MD Smet de","year":"2001","unstructured":"de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm. 2001;9:85\u201392.","journal-title":"Ocul Immunol Inflamm"},{"key":"328_CR28","first-page":"S32","volume":"27","author":"G Mumcu","year":"2009","unstructured":"Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2009;27:S32\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"328_CR29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1348-0421.1992.tb02083.x","volume":"36","author":"K Yokota","year":"1992","unstructured":"Yokota K, Hayashi S, Fujii N, et al. Antibody response to oral streptococci in Beh\u00e7et\u2019s disease. Microbiol Immunol. 1992;36:815\u201322.","journal-title":"Microbiol Immunol"},{"key":"328_CR30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0003-9969(90)90113-O","volume":"35","author":"E Isogai","year":"1990","unstructured":"Isogai E, Ohno S, Kotake S, et al. Chemiluminescence of neutrophils from patients with Beh\u00e7et\u2019s disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol. 1990;35:43\u20138.","journal-title":"Arch Oral Biol"},{"key":"328_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000246336","volume":"192","author":"M Calg\u00fcneri","year":"1996","unstructured":"Calg\u00fcneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Beh\u00e7et\u2019s disease. Dermatology. 1996;192:125\u20138.","journal-title":"Dermatology"},{"key":"328_CR32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0008-8749(92)90207-6","volume":"140","author":"S Hirohata","year":"1992","unstructured":"Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet\u2019s disease. Cell Immunol. 1992;140:410\u20139.","journal-title":"Cell Immunol"},{"key":"328_CR33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/eji.1830240712","volume":"24","author":"M Mochizuki","year":"1994","unstructured":"Mochizuki M, Suzuki N, Takeno M, Nagafuchi H, Harada T, Kaneoka H. Fine antigen specificity of human gamma delta T cell lines (V gamma 9\u00a0+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol. 1994;24:1536\u201343.","journal-title":"Eur J Immunol"},{"key":"328_CR34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, T\u00fcrk\u00f6z Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediat Inflamm. 2002;11:87\u201393.","journal-title":"Mediat Inflamm"},{"key":"328_CR35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1076\/ocii.7.2.69.4018","volume":"7","author":"T Tanaka","year":"1999","unstructured":"Tanaka T, Yamakawa N, Koike N, Suzuki J, Mizuno F, Usui M. Beh\u00e7et\u2019s disease and antibody titers to various heatshock protein 60s. Ocul Immunol Inflamm. 1999;7:69\u201374.","journal-title":"Ocul Immunol Inflamm"},{"key":"328_CR36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10067-006-0416-x","volume":"26","author":"TZ Apan","year":"2007","unstructured":"Apan TZ, G\u00fcrsel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin associated gene-A in Beh\u00e7et\u2019s disease. Clin Rheumatol. 2007;26:885\u20139.","journal-title":"Clin Rheumatol"},{"key":"328_CR37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C. Current concepts in the etiology and treatment of Beh\u00e7et disease. Surv Ophthalmol. 2005;50:297\u2013350.","journal-title":"Surv Ophthalmol"},{"key":"328_CR38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2230.2006.02330.x","volume":"32","author":"EB Baskan","year":"2007","unstructured":"Baskan EB, Yilmaz E, Saricaoglu H, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Beh\u00e7et\u2019s disease. Clin Exp Dermatol. 2007;32:186\u201390.","journal-title":"Clin Exp Dermatol"},{"key":"328_CR39","first-page":"S32","volume":"27","author":"G Mumcu","year":"2009","unstructured":"Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2009;27:S32\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"328_CR40","first-page":"287","volume":"32","author":"N Inanc","year":"2005","unstructured":"Inanc N, Mumcu G, Birtas E, et al. Serum mannose-binding lectin levels are decreased in behcet\u2019s disease and associated with disease severity. J Rheumatol. 2005;32:287\u201391.","journal-title":"J Rheumatol"},{"key":"328_CR41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00296-007-0470-y","volume":"28","author":"S Yavuz","year":"2008","unstructured":"Yavuz S, Elbir Y, Tulunay A, Eksioglu-Demiralp E, Direskeneli H. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet\u2019s disease etiopathogenesis. Rheumatol Int. 2008;28:401\u20136.","journal-title":"Rheumatol Int"},{"issue":"4","key":"328_CR42","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1753425913498042","volume":"20","author":"N Seoudi","year":"2014","unstructured":"Seoudi N, Bergmeier LA, Hagi-Pavli E, Bibby D, Curtis MA, Fortune F. The role of TLR2 and 4 in Behcet\u2019s disease pathogenesis. Innate Immun. 2014;20(4):412\u201322.","journal-title":"Innate Immun"},{"key":"328_CR43","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1167\/iovs.13-12159","volume":"54","author":"X Liu","year":"2013","unstructured":"Liu X, Wang C, Ye Z, Kijlstra A, Yang P. Higher expression of toll-like receptors 2, 3, 4, and 8 in ocular Behcet\u2019s disease. Investig Ophthalmol Vis Sci. 2013;54:6012\u20137.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"328_CR44","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/ken109","volume":"47","author":"JE Do","year":"2008","unstructured":"Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of toll-like receptors of monocytes from patients with Behcet\u2019s disease. Rheumatology (Oxford). 2008;47:840\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"328_CR45","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1167\/iovs.12-11047","volume":"54","author":"L Liang","year":"2013","unstructured":"Liang L, Tan X, Zhou Q, et al. IL-1\u03b2 triggered by peptidoglycan and lipopolysaccharide through TLR2\/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Beh\u00e7et\u2019s disease. Investig Ophthalmol Vis Sci. 2013;54:402\u201314.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"328_CR46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","volume":"60","author":"H Direskeneli","year":"2001","unstructured":"Direskeneli H. Beh\u00e7et\u2019s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996\u20131002.","journal-title":"Ann Rheum Dis"},{"key":"328_CR47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/0962935031000097754","volume":"12","author":"K Erkili\u00e7","year":"2003","unstructured":"Erkili\u00e7 K, Evereklioglu C, Cekmen M, Ozkiris A, Duygulu F, Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Beh\u00e7et\u2019s disease: original contributions\/clinical and laboratory investigations. Mediat Inflamm. 2003;12:107\u201316.","journal-title":"Mediat Inflamm"},{"key":"328_CR48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00296-005-0612-z","volume":"25","author":"M Calis","year":"2005","unstructured":"Calis M, Ates F, Yazici C, et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Beh\u00e7et\u2019s disease. Rheumatol Int. 2005;25:452\u20136.","journal-title":"Rheumatol Int"},{"key":"328_CR49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-4632.2006.02892.x","volume":"45","author":"F Canpolat","year":"2006","unstructured":"Canpolat F, Unver M, Eskio\u011flu F, K\u00f6sebalaban S, Durmazlar SP. Serum and erythrocyte adenosine deaminase activities in patients with Beh\u00e7et\u2019s disease. Int J Dermatol. 2006;45:1053\u20136.","journal-title":"Int J Dermatol"},{"key":"328_CR50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","volume":"31","author":"K Hamzaoui","year":"2002","unstructured":"Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Beh\u00e7et\u2019s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205\u201310.","journal-title":"Scand J Rheumatol"},{"key":"328_CR51","first-page":"329","volume":"25","author":"S Raziuddin","year":"1998","unstructured":"Raziuddin S, Al-Dalaan A, Bahabri S, Siraj AK, Al-Sedairy S. Divergent cytokine production profile in Beh\u00e7et\u2019s disease. Altered Th1\/Th2 cell cytokine pattern. J Rheumatol. 1998;25:329\u201333.","journal-title":"J Rheumatol"},{"key":"328_CR52","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/03009740600905380","volume":"35","author":"AM Dalghous","year":"2006","unstructured":"Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet\u2019s disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006;35:472\u20135.","journal-title":"Scand J Rheumatol"},{"key":"328_CR53","first-page":"996","volume":"39","author":"N Sugi-Ikai","year":"1998","unstructured":"Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Beh\u00e7et\u2019s disease. Invest Ophthalmol Vis Sci. 1998;39:996\u20131004.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"328_CR54","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z","volume":"42","author":"MA Frassanito","year":"1999","unstructured":"Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Beh\u00e7et\u2019s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 1999;42:1967\u201374.","journal-title":"Arthritis Rheum"},{"key":"328_CR55","first-page":"1283","volume":"28","author":"L Boiardi","year":"2001","unstructured":"Boiardi L, Salvarani C, Casali B, et al. Intercellular adhesion molecule-1 gene polymorphisms in Beh\u00e7et\u2019s disease. J Rheumatol. 2001;28:1283\u20137.","journal-title":"J Rheumatol"},{"key":"328_CR56","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/art.20334","volume":"50","author":"M Ben Ahmed","year":"2004","unstructured":"Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Beh\u00e7et\u2019s disease. Arthritis Rheum. 2004;50:2291\u20135.","journal-title":"Arthritis Rheum"},{"key":"328_CR57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1076\/ocii.12.1.53.28062","volume":"12","author":"Y Bardak","year":"2004","unstructured":"Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor alpha, complement, and immunoglobulin levels in Beh\u00e7et\u2019s disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"328_CR58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3121\/cmr.4.2.147","volume":"4","author":"N Suzuki","year":"2006","unstructured":"Suzuki N, Nara K, Suzuki T. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet\u2019s disease. Clin Med Res. 2006;4:147\u201351.","journal-title":"Clin Med Res"},{"key":"328_CR59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2249.2005.02695.x","volume":"139","author":"Y Imamura","year":"2005","unstructured":"Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet\u2019s disease. Clin Exp Immunol. 2005;139:371\u20138.","journal-title":"Clin Exp Immunol"},{"key":"328_CR60","first-page":"128","volume":"24","author":"B Turan","year":"1997","unstructured":"Turan B, Gallati H, Erdi H, G\u00fcrler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bech\u00e7et\u2019s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128\u201332.","journal-title":"J Rheumatol"},{"key":"328_CR61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000018426","volume":"201","author":"J Katsantonis","year":"2000","unstructured":"Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Beh\u00e7et\u2019s disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology. 2000;201:37\u20139.","journal-title":"Dermatology"},{"key":"328_CR62","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00296-005-0029-8","volume":"26","author":"U Musabak","year":"2006","unstructured":"Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Beh\u00e7et\u2019s disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int. 2006;26:545\u201350.","journal-title":"Rheumatol Int"},{"key":"328_CR63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/03009740701747137","volume":"37","author":"B Turan","year":"2008","unstructured":"Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Beh\u00e7et\u2019s disease. Scand J Rheumatol. 2008;37:135\u201341.","journal-title":"Scand J Rheumatol"},{"key":"328_CR64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-4632.2009.03905.x","volume":"48","author":"SP Durmazlar","year":"2009","unstructured":"Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet\u2019s disease: high levels may indicate vascular involvement. Int J Dermatol. 2009;48:259\u201364.","journal-title":"Int J Dermatol"},{"key":"328_CR65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1076\/ocii.12.1.53.28062","volume":"12","author":"Y Bardak","year":"2004","unstructured":"Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Beh\u00e7et\u2019s disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"328_CR66","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/112067210901900616","volume":"19","author":"Y Ozdamar","year":"2009","unstructured":"Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol. 2009;19:998\u20131003.","journal-title":"Eur J Ophthalmol"},{"key":"328_CR67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","volume":"44","author":"G Akman-Demir","year":"2008","unstructured":"Akman-Demir G, T\u00fcz\u00fcn E, I\u00e7\u00f6z S, Ye\u015filot N, et al. Interleukin-6 in neuro-Beh\u00e7et\u2019s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373\u20136.","journal-title":"Cytokine"},{"key":"328_CR68","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar3824","volume":"14","author":"S Sugita","year":"2012","unstructured":"Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh\u00e7et\u2019s disease. Arthritis Res Ther. 2012;14:R99.","journal-title":"Arthritis Res Ther"},{"key":"328_CR69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2249.2011.04543.x","volume":"168","author":"J Shimizu","year":"2012","unstructured":"Shimizu J, Takai K, Fujiwara N, et al. Excessive CD4\u00a0+\u00a0T cells co-expressing interleukin-17 and interferon-\u03b3 in patients with Beh\u00e7et\u2019s disease. Clin Exp Immunol. 2012;168:68\u201374.","journal-title":"Clin Exp Immunol"},{"key":"328_CR70","first-page":"S71","volume":"29","author":"K Hamzaoui","year":"2011","unstructured":"Hamzaoui K. Th17 cells in Beh\u00e7et\u2019s disease: a new immunoregulatory axis. Clin Exp Rheumatol. 2011;29:S71\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"328_CR71","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","volume":"128","author":"G Geri","year":"2011","unstructured":"Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease. J Allergy Clin Immunol. 2011;128:655\u201364.","journal-title":"J Allergy Clin Immunol"},{"key":"328_CR72","first-page":"393","volume":"47","author":"L Liang","year":"2011","unstructured":"Liang L, Wang H, Peng XY, Zhao M. The changes of Th lymphocyte subsets in patients with Behcet disease. Zhonghua Yan Ke Za Zhi. 2011;47:393\u20137.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"328_CR73","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/annrheumdis-2011-200288","volume":"72","author":"YJ Lee","year":"2013","unstructured":"Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet\u2019s disease. Ann Rheum Dis. 2013;72:1510\u20136.","journal-title":"Ann Rheum Dis"},{"key":"328_CR74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1744-313X.2007.00655.x","volume":"34","author":"R Gunesacar","year":"2007","unstructured":"Gunesacar R, Erken E, Bozkurt B, et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet\u2019s disease. Int J Immunogenet. 2007;34:45\u20139.","journal-title":"Int J Immunogenet"},{"key":"328_CR75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1399-0039.2009.01303.x","volume":"74","author":"KS Park","year":"2009","unstructured":"Park KS, Baek JA, Do JE, Bang D, Lee ES. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet\u2019s disease. Tissue Antigens. 2009;74:222\u20137.","journal-title":"Tissue Antigens"},{"key":"328_CR76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-0039.2008.01186.x","volume":"73","author":"I Ben Dhifallah","year":"2009","unstructured":"Ben Dhifallah I, Chelbi H, Braham A, Hamzaoui K, Houman MH. CTLA-4 +49A\/G polymorphism is associated with Beh\u00e7et\u2019s disease in a Tunisian population. Tissue Antigens. 2009;73:213\u20137.","journal-title":"Tissue Antigens"},{"key":"328_CR77","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar3824","volume":"14","author":"S Sugita","year":"2012","unstructured":"Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh\u00e7et\u2019s disease. Arthritis Res Ther. 2012;14:R99.","journal-title":"Arthritis Res Ther"},{"key":"328_CR78","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00296-005-0040-0","volume":"26","author":"S Pay","year":"2006","unstructured":"Pay S, Erdem H, Pekel A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Beh\u00e7et\u2019s disease. Does interleukin-1beta play a major role in Beh\u00e7et\u2019s synovitis? Rheumatol Int. 2006;26:608\u201313.","journal-title":"Rheumatol Int"},{"key":"328_CR79","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1529-0131(200107)44:7<1707::AID-ART295>3.0.CO;2-P","volume":"44","author":"CH Suh","year":"2001","unstructured":"Suh CH, Park YB, Song J, Lee CH, Lee SK. Oligoclonal B lymphocyte expansion in the synovium of a patient with Beh\u00e7et\u2019s disease. Arthritis Rheum. 2001;44:1707\u201312.","journal-title":"Arthritis Rheum"},{"key":"328_CR80","first-page":"826","volume":"26","author":"E Eksioglu-Demiralp","year":"1999","unstructured":"Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Beh\u00e7et\u2019s disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826\u201332.","journal-title":"J Rheumatol"},{"key":"328_CR81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clin.1993.1059","volume":"67","author":"AO Ayd\u00ecntug","year":"1993","unstructured":"Ayd\u00ecntug AO, Tokg\u00f6z G, D\u2019Cruz DP, et al. Antibodies to endothelial cells in patients with Beh\u00e7et\u2019s disease. Clin Immunol Immunopathol. 1993;67:157\u201362.","journal-title":"Clin Immunol Immunopathol"},{"key":"328_CR82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02208085","volume":"14","author":"H Direskeneli","year":"1995","unstructured":"Direskeneli H, Keser G, D\u2019Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Beh\u00e7et\u2019s disease. Clin Rheumatol. 1995;14:55\u201361.","journal-title":"Clin Rheumatol"},{"key":"328_CR83","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2249.2005.02760.x","volume":"140","author":"SP Mahesh","year":"2005","unstructured":"Mahesh SP, Li Z, Buggage R, et al. Alpha tropomyosin as a self-antigen in patients with Beh\u00e7et\u2019s disease. Clin Exp Immunol. 2005;140:368\u201375.","journal-title":"Clin Exp Immunol"},{"key":"328_CR84","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/1521-4141(200202)32:2<356::AID-IMMU356>3.0.CO;2-9","volume":"32","author":"F Mor","year":"2002","unstructured":"Mor F, Weinberger A, Cohen IR. Identification of alpha-tropomyosin as a target self-antigen in Beh\u00e7et\u2019s syndrome. Eur J Immunol. 2002;32:356\u201365.","journal-title":"Eur J Immunol"},{"key":"328_CR85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0002-9343(01)01048-8","volume":"112","author":"G Espinosa","year":"2002","unstructured":"Espinosa G, Font J, T\u00e0ssies D, Vidaller A, et al. Vascular involvement in Beh\u00e7et\u2019s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37\u201343.","journal-title":"Am J Med"},{"key":"328_CR86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1067\/mjd.2002.118338","volume":"46","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Beh\u00e7et\u2019s disease: is it a new activity marker? J Am Acad Dermatol. 2002;46:50\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"328_CR87","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/09629350310001599710","volume":"12","author":"C Evereklioglu","year":"2003","unstructured":"Evereklioglu C, Cekmen M, Ozkiri\u015f A, Karaba\u015f L, Cali\u015f M. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Beh\u00e7et\u2019s disease. Mediat Inflamm. 2003;12:255\u20136.","journal-title":"Mediat Inflamm"},{"key":"328_CR88","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00006982-200206000-00012","volume":"22","author":"G Yilmaz","year":"2002","unstructured":"Yilmaz G, Sizmaz S, Yilmaz ED, Duman S, Aydin P. Aqueous humor nitric oxide levels in patients with Beh\u00e7et disease. Retina. 2002;22:330\u20135.","journal-title":"Retina"},{"key":"328_CR89","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2133.2005.06543.x","volume":"153","author":"S Buldanlioglu","year":"2005","unstructured":"Buldanlioglu S, Turkmen S, Ayabakan HB, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Beh\u00e7et\u2019s disease. Br J Dermatol. 2005;153:526\u201330.","journal-title":"Br J Dermatol"},{"key":"328_CR90","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10067-004-1015-3","volume":"24","author":"F Duygulu","year":"2005","unstructured":"Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Beh\u00e7et\u2019s disease: a pilot study. Clin Rheumatol. 2005;24:324\u201330.","journal-title":"Clin Rheumatol"},{"key":"328_CR91","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1365-4362.2003.01688.x","volume":"42","author":"M Cekmen","year":"2003","unstructured":"Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Beh\u00e7et\u2019s syndrome. Int J Dermatol. 2003;42:870\u20135.","journal-title":"Int J Dermatol"},{"key":"328_CR92","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2009.05.005","volume":"213","author":"K Hamzaoui","year":"2009","unstructured":"Hamzaoui K, Ayed K, Hamza M, Hamzaoui A. VEGF and mRNA VEGF expression in CSF from Beh\u00e7et\u2019s disease with neurological involvement. J Neuroimmunol. 2009;213:148\u201353.","journal-title":"J Neuroimmunol"},{"key":"328_CR93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0002-9343(01)01048-8","volume":"112","author":"G Espinosa","year":"2002","unstructured":"Espinosa G, Font J, T\u00e0ssies D, et al. Vascular involvement in Beh\u00e7et\u2019s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37\u201343.","journal-title":"Am J Med"},{"key":"328_CR94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0609.1996.tb00499.x","volume":"57","author":"IC Haznedaroglu","year":"1996","unstructured":"Haznedaroglu IC, Ozcebe O, Celik I, D\u00fcndar SV, Kirazhi S. Haemostatic markers of procoagulant imbalance in Beh\u00e7et\u2019s disease. Eur J Haematol. 1996;57:107\u20138.","journal-title":"Eur J Haematol"},{"key":"328_CR95","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1076029606293430","volume":"12","author":"S Akar","year":"2006","unstructured":"Akar S, Ozcan MA, Ate\u015f H, et al. Circulated activated platelets and increased platelet reactivity in patients with Beh\u00e7et\u2019s disease. Clin Appl Thromb Hemost. 2006;12:451\u20137.","journal-title":"Clin Appl Thromb Hemost"},{"key":"328_CR96","first-page":"S53","volume":"23","author":"S Yurdakul","year":"2005","unstructured":"Yurdakul S, Hekim N, Soysal T, et al. Fibrinolytic activity and d-dimer levels in Beh\u00e7et\u2019s syndrome. Clin Exp Rheumatol. 2005;23:S53\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"328_CR97","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1346-8138.1994.tb01762.x","volume":"21","author":"R Itoh","year":"1994","unstructured":"Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizoguchi M. Interleukin 8 in Beh\u00e7et\u2019s disease. J Dermatol. 1994;21:397\u2013404.","journal-title":"J Dermatol"},{"key":"328_CR98","first-page":"904","volume":"22","author":"A Al-Dalaan","year":"1995","unstructured":"Al-Dalaan A, Al-Sedairy S, Al-Balaa S, et al. Enhanced interleukin 8 secretion in circulation of patients with Beh\u00e7et\u2019s disease. J Rheumatol. 1995;22:904\u20137.","journal-title":"J Rheumatol"},{"key":"328_CR99","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.55.2.128","volume":"55","author":"S Sahin","year":"1996","unstructured":"Sahin S, Ako\u011flu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Beh\u00e7et\u2019s disease. Ann Rheum Dis. 1996;55:128\u201333.","journal-title":"Ann Rheum Dis"},{"key":"328_CR100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1006\/clim.1999.4687","volume":"91","author":"G Triolo","year":"1999","unstructured":"Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Beh\u00e7et\u2019s disease: moderate correlation with antiendothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol. 1999;91:330\u20137.","journal-title":"Clin Immunol"},{"key":"328_CR101","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archderm.140.5.570","volume":"140","author":"T Kawakami","year":"2004","unstructured":"Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140:570\u20134.","journal-title":"Arch Dermatol"},{"key":"328_CR102","first-page":"S52","volume":"27","author":"K Hamzaoui","year":"2009","unstructured":"Hamzaoui K, Ma\u00eetre B, Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2009;27:S52\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"328_CR103","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.rdc.2013.02.010","volume":"39","author":"G Hatemi","year":"2013","unstructured":"Hatemi G, Yazici Y, Yazici H. Beh\u00e7et\u2019s syndrome. Rheum Dis Clin North Am. 2013;39(2):245\u201361.","journal-title":"Rheum Dis Clin North Am"},{"key":"328_CR104","first-page":"241","volume":"107","author":"N Yamashita","year":"1997","unstructured":"Yamashita N, Kaneoka H, Kaneko S, Takeno M, et al. Role of gammadelta T lymphocytein the development of Behcet\u2019s disease. Clin Exp Rheum. 1997;107:241\u20137.","journal-title":"Clin Exp Rheum"},{"key":"328_CR105","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(96)90868-5","volume":"347","author":"A Hasan","year":"1996","unstructured":"Hasan A, Fortune F, Wilson A, et al. Role of T-cells in pathogenesis and diagnosis of Behcet\u2019s Dis. Lancet. 1996;347:789\u201394.","journal-title":"Lancet"},{"key":"328_CR106","first-page":"S19","volume":"21","author":"CC Zouboulis","year":"2003","unstructured":"Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Beh\u00e7et\u2019s disease in Greece. Clin Exp Rheumatol. 2003;21:S19\u201326.","journal-title":"Clin Exp Rheumatol"},{"key":"328_CR107","unstructured":"O\u2019Duffy JD. Behcet\u2019s syndrome. In: Primer on the rheumatic diseases, 10th, Arthritis Foundation, Atlanta 1993. vol. 29, p. 206."},{"key":"328_CR108","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0022-5347(05)67908-6","volume":"163","author":"VG Kaklamani","year":"2000","unstructured":"Kaklamani VG, Vaiopoulos G, Markomichelakis N, Kaklamanis P. Recurrent epididymo-orchitis in patients with Beh\u00e7et\u2019s disease. J Urol. 2000;163:487\u20139.","journal-title":"J Urol"},{"key":"328_CR109","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/01.ju.0000081957.90395.4c","volume":"170","author":"YH Cho","year":"2003","unstructured":"Cho YH, Jung J, Lee KH, Bang D, Lee ES, Lee S. Clinical features of patients with Beh\u00e7et\u2019s disease and epididymitis. J Urol. 2003;170:1231\u20133.","journal-title":"J Urol"},{"key":"328_CR110","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/ard.60.11.1074","volume":"60","author":"E Diri","year":"2001","unstructured":"Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Beh\u00e7et\u2019s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 2001;60:1074\u20136.","journal-title":"Ann Rheum Dis"},{"key":"328_CR111","first-page":"2393","volume":"29","author":"R Tunc","year":"2002","unstructured":"Tunc R, Keyman E, Melikoglu M, Fresko I, Yazici H. Target organ associations in Turkish patients with Beh\u00e7et\u2019s disease: a cross sectional study by exploratory factor analysis. J Rheumatol. 2002;29:2393\u20136.","journal-title":"J Rheumatol"},{"key":"328_CR112","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/ard.2003.017467","volume":"63","author":"G Hatemi","year":"2004","unstructured":"Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behcet\u2019s syndrome are not sterile. Ann Rheum Dis. 2004;63:1450\u20132.","journal-title":"Ann Rheum Dis"},{"key":"328_CR113","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0190-9622(88)70264-9","volume":"19","author":"JL Jorizzo","year":"1988","unstructured":"Jorizzo JL, Solomon AR, Zanolli MD, Leshin B. Neutrophilic vascular reactions. J Am Acad Dermatol. 1988;19:983\u20131005.","journal-title":"J Am Acad Dermatol"},{"key":"328_CR114","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/bjo.86.2.140","volume":"86","author":"T Matsuo","year":"2002","unstructured":"Matsuo T, Itami M, Nakagawa H, Nagayama M. The incidence and pathology of conjunctival ulceration in Beh\u00e7et\u2019s syndrome. Br J Ophthalmol. 2002;86:140\u20133.","journal-title":"Br J Ophthalmol"},{"key":"328_CR115","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0161-6420(03)00265-3","volume":"110","author":"E Zamir","year":"2003","unstructured":"Zamir E, Bodaghi B, Tugal-Tutkun I, et al. Conjunctival ulcers in Beh\u00e7et\u2019s disease. Ophthalmology. 2003;110:1137\u201341.","journal-title":"Ophthalmology"},{"key":"328_CR116","first-page":"402","volume":"19","author":"Y Ko\u00e7","year":"1992","unstructured":"Ko\u00e7 Y, G\u00fcll\u00fc I, Akpek G, et al. Vascular involvement in Beh\u00e7et\u2019s disease. J Rheumatol. 1992;19:402\u201310.","journal-title":"J Rheumatol"},{"key":"328_CR117","first-page":"8","volume":"5","author":"E Seyahi","year":"2007","unstructured":"Seyahi E, Melikoglu M, Yazici H. Clinical features and diagnosis of Behcet\u2019s syndrome. Int J Adv Rheumatol. 2007;5:8.","journal-title":"Int J Adv Rheumatol"},{"key":"328_CR118","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60\u201376.","journal-title":"Medicine (Baltimore)"},{"key":"328_CR119","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1378\/chest.127.6.2243","volume":"127","author":"O Uzun","year":"2005","unstructured":"Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005;127:2243\u201353.","journal-title":"Chest"},{"key":"328_CR120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","volume":"91","author":"E Seyahi","year":"2012","unstructured":"Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients. Medicine (Baltimore). 2012;91:35\u201348.","journal-title":"Medicine (Baltimore)"},{"key":"328_CR121","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1378\/chest.127.6.2243","volume":"127","author":"O Uzun","year":"2005","unstructured":"Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005;127:2243\u201353.","journal-title":"Chest"},{"issue":"7","key":"328_CR122","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3899\/jrheum.131227","volume":"41","author":"C Sibley","year":"2014","unstructured":"Sibley C, Yazici Y, Tascilar K, et al. Beh\u00e7et syndrome manifestations and activity in the United States versus Turkey: a cross-sectional cohort comparison. J Rheumatol. 2014;41(7):1379\u201384.","journal-title":"J Rheumatol"},{"key":"328_CR123","first-page":"858","volume":"92","author":"Y Bayraktar","year":"1997","unstructured":"Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd\u2013Chiari syndrome: a common complication of Beh\u00e7et\u2019s disease. Am J Gastroenterol. 1997;92:858\u201362.","journal-title":"Am J Gastroenterol"},{"key":"328_CR124","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/03009749709115831","volume":"26","author":"HA Kim","year":"1997","unstructured":"Kim HA, Choi KW, Song YW. Arthropathy in Beh\u00e7et\u2019s disease. Scand J Rheumatol. 1997;26:125\u20139.","journal-title":"Scand J Rheumatol"},{"key":"328_CR125","first-page":"S110","volume":"26","author":"N Moses Alder","year":"2008","unstructured":"Moses Alder N, Fisher M, Yazici Y. Beh\u00e7et\u2019s syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clin Exp Rheumatol. 2008;26:S110\u20133.","journal-title":"Clin Exp Rheumatol"},{"key":"328_CR126","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/sarh.2002.31721","volume":"31","author":"T Akpolat","year":"2002","unstructured":"Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S. Renal Beh\u00e7et\u2019s disease: a cumulative analysis. Semin Arthritis Rheum. 2002;31:317\u201337.","journal-title":"Semin Arthritis Rheum"},{"key":"328_CR127","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0167-5273(97)00120-4","volume":"61","author":"O Goldeli","year":"1997","unstructured":"Goldeli O, Ural D, Komsuo\u011flu B, A\u011fa\u00e7diken A, Dursun E, Cetinarslan B. Abnormal QT dispersion in Beh\u00e7et\u2019s disease. Int J Cardiol. 1997;61:55\u20139.","journal-title":"Int J Cardiol"},{"key":"328_CR128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/ard.56.3.205","volume":"56","author":"DL Huong","year":"1997","unstructured":"Huong DL, Wechsler B, Papo T, et al. Endomyocardial fibrosis in Beh\u00e7et\u2019s disease. Ann Rheum Dis. 1997;56:205\u20138.","journal-title":"Ann Rheum Dis"},{"key":"328_CR129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1536\/jhj.43.389","volume":"43","author":"C G\u00fcrg\u00fcn","year":"2002","unstructured":"G\u00fcrg\u00fcn C, Ercan E, Ceyhan C, et al. Cardiovascular involvement in Beh\u00e7et\u2019s disease. Jpn HeartJ. 2002;43:389\u201398.","journal-title":"Jpn HeartJ"},{"key":"328_CR130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e3182428f49","volume":"91","author":"G Geri","year":"2012","unstructured":"Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Beh\u00e7et disease: a series of 52 patients and review of the literature. Medicine (Baltimore). 2012;91:25\u201334.","journal-title":"Medicine (Baltimore)"},{"issue":"45","key":"328_CR131","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/kei257","volume":"6","author":"CG Barnes","year":"2006","unstructured":"Barnes CG. Treatment of Behcet\u2019s syndrome. Rheumatology (Oxford). 2006;6(45):245\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"328_CR132","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","volume":"45","author":"C Mat","year":"2006","unstructured":"Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Beh\u00e7et\u2019s syndrome. Rheumatology (Oxford). 2006;45:348\u201352.","journal-title":"Rheumatology (Oxford)"},{"key":"328_CR133","unstructured":"Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet\u2019s syndrome. Cochrane Database Syst Rev. 2000. (doppia nota 140)."},{"key":"328_CR134","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"S Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, Mat C, et al. A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum. 2001;44:2686\u201392.","journal-title":"Arthritis Rheum"},{"key":"328_CR135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/sarh.2001.19819","volume":"30","author":"VG Kaklamani","year":"2001","unstructured":"Kaklamani VG, Kaklamanis PG. Treatment of Beh\u00e7et\u2019s disease\u2013an update. Semin Arthritis Rheum. 2001;30:299\u2013312.","journal-title":"Semin Arthritis Rheum"},{"key":"328_CR136","first-page":"399","volume":"65","author":"E Aktulga","year":"1980","unstructured":"Aktulga E, Alta\u00e7 M, M\u00fcft\u00fcoglu A, et al. A double blind study of colchicine in Beh\u00e7et\u2019s disease. Haematologica. 1980;65:399\u2013402.","journal-title":"Haematologica"},{"key":"328_CR137","first-page":"148","volume":"23","author":"H Kazokoglu","year":"1991","unstructured":"Kazokoglu H, Saat\u00e7i O, Cuhadaroglu H, Eldem B. Long-term effects of cyclophosphamide and colchicine treatment in Beh\u00e7et\u2019s disease. Ann Ophthalmol. 1991;23:148\u201351.","journal-title":"Ann Ophthalmol"},{"key":"328_CR138","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med. 1990;322:281\u20135.","journal-title":"N Engl J Med"},{"key":"328_CR139","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/acr.20308","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Beh\u00e7et\u2019s disease. Arthritis Care Res (Hoboken). 2010;62:1733\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"328_CR140","unstructured":"Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet\u2019s syndrome. Cochrane Database Syst Rev. 2000. (doppia nota 133)."},{"key":"328_CR141","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241\u20133.","journal-title":"Br J Ophthalmol"},{"key":"328_CR142","first-page":"321","volume":"25","author":"LS Atmaca","year":"1994","unstructured":"Atmaca LS, Batioglu F. The efficacy of cyclosporin-a in the treatment of Beh\u00e7et\u2019s disease. Ophthalmic Surg. 1994;25:321\u20137.","journal-title":"Ophthalmic Surg"},{"key":"328_CR143","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jop.1994.10.553","volume":"10","author":"H Sajjadi","year":"1994","unstructured":"Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Beh\u00e7et\u2019s disease. J Ocul Pharmacol. 1994;10:553\u201360.","journal-title":"J Ocul Pharmacol"},{"key":"328_CR144","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9394(14)72840-5","volume":"118","author":"SM Whitcup","year":"1994","unstructured":"Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Beh\u00e7et\u2019s disease. Am J Ophthalmol. 1994;118:39\u201345.","journal-title":"Am J Ophthalmol"},{"key":"328_CR145","first-page":"136","volume":"20","author":"D BenEzra","year":"1988","unstructured":"BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome. Transpl Proc. 1988;20:136\u201343.","journal-title":"Transpl Proc"},{"key":"328_CR146","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"I K\u00f6tter","year":"2006","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Beh\u00e7et\u2019s disease under cyclosporin A (CSA) than under other medications\u2013results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482\u20136.","journal-title":"Clin Rheumatol"},{"key":"328_CR147","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jop.1994.10.553","volume":"10","author":"H Sajjadi","year":"1994","unstructured":"Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Beh\u00e7et\u2019s disease. J Ocul Pharmacol. 1994;10:553\u201360.","journal-title":"J Ocul Pharmacol"},{"key":"328_CR148","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1517\/13543784.9.9.1993","volume":"9","author":"T Sakane","year":"2000","unstructured":"Sakane T, Takeno M. Novel approaches to Beh\u00e7et\u2019s disease. Expert Opin Investig Drugs. 2000;9:1993\u20132005.","journal-title":"Expert Opin Investig Drugs"},{"key":"328_CR149","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.bor.0000197995.27579.9b","volume":"18","author":"N Pipitone","year":"2006","unstructured":"Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades-Beh\u00e7et\u2019s disease. Curr Opin Rheumatol. 2006;18:3\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"328_CR150","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet\u2019s disease\u2014review and basis for recommendations. Rheumatology (Oxford). 2007;46:736.","journal-title":"Rheumatology (Oxford)"},{"key":"328_CR151","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med. 2004;140:404\u20136.","journal-title":"Ann Intern Med"},{"key":"328_CR152","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Beh\u00e7et\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"328_CR153","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98\u2013105.","journal-title":"J Rheumatol"},{"key":"328_CR154","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","volume":"18","author":"A Bawazeer","year":"2010","unstructured":"Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Beh\u00e7et disease. Ocul Immunol Inflamm. 2010;18:226\u201332.","journal-title":"Ocul Immunol Inflamm"},{"key":"328_CR155","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","volume":"75","author":"P Pivetti-Pezzi","year":"1997","unstructured":"Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G. Interferon alpha for ocular Beh\u00e7et\u2019s disease. Acta Ophthalmol Scand. 1997;75:720\u20132.","journal-title":"Acta Ophthalmol Scand"},{"key":"328_CR156","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","volume":"21","author":"JC Nichols","year":"2001","unstructured":"Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol. 2001;21:109\u201311.","journal-title":"J Neuroophthalmol"},{"key":"328_CR157","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","volume":"134","author":"CC Zouboulis","year":"1998","unstructured":"Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa. Arch Dermatol. 1998;134:1010\u20136.","journal-title":"Arch Dermatol"},{"key":"328_CR158","first-page":"1098","volume":"21","author":"V Hamuryudan","year":"1994","unstructured":"Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Beh\u00e7et\u2019s syndrome. J Rheumatol. 1994;21:1098\u2013100.","journal-title":"J Rheumatol"},{"key":"328_CR159","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E Alpsoy","year":"2002","unstructured":"Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467\u201371.","journal-title":"Arch Dermatol"},{"key":"328_CR160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00347-003-0927-7","volume":"101","author":"CM Deuter","year":"2004","unstructured":"Deuter CM, K\u00f6tter I, K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. Ocular involvement in Beh\u00e7et\u2019s disease: first 5-year results for visual development after treatment with interferon alfa-2a. Ophthalmologe. 2004;101:129\u201334.","journal-title":"Ophthalmologe"},{"key":"328_CR161","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423\u201331.","journal-title":"Br J Ophthalmol"},{"key":"328_CR162","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","volume":"31","author":"E Alpsoy","year":"1994","unstructured":"Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Beh\u00e7et\u2019s disease. J Am Acad Dermatol. 1994;31:617\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"328_CR163","first-page":"1938","volume":"25","author":"JD O\u2019Duffy","year":"1998","unstructured":"O\u2019Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Beh\u00e7et\u2019s disease. J Rheumatol. 1998;25:1938\u201344.","journal-title":"J Rheumatol"},{"key":"328_CR164","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/ken172","volume":"47","author":"JB Kuemmerle-Deschner","year":"2008","unstructured":"Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I. Interferon-alpha-a new therapeutic option in refractory juvenile Beh\u00e7et\u2019s disease with CNS involvement. Rheumatology. 2008;47:1051.","journal-title":"Rheumatology"},{"key":"328_CR165","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/jop.2011.0238","volume":"28","author":"FN Yal\u00e7indag","year":"2012","unstructured":"Yal\u00e7indag FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet\u2019s disease. J Ocul Pharmacol Ther. 2012;28:439.","journal-title":"J Ocul Pharmacol Ther"},{"key":"328_CR166","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum. 2004;33:320.","journal-title":"Semin Arthritis Rheum"},{"key":"328_CR167","first-page":"S64","volume":"29","author":"E Shugaiv","year":"2011","unstructured":"Shugaiv E, T\u00fcz\u00fcn E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Beh\u00e7et\u2019s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29:S64\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"328_CR168","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000051781","volume":"203","author":"YD Adler","year":"2001","unstructured":"Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Beh\u00e7et\u2019s disease. Dermatology. 2001;203:322\u20134.","journal-title":"Dermatology"},{"key":"328_CR169","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443\u201350.","journal-title":"Ann Intern Med"},{"key":"328_CR170","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246.","journal-title":"Int J Rheum Dis"},{"key":"328_CR171","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bjo.85.11.1287","volume":"85","author":"N Seider","year":"2001","unstructured":"Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Beh\u00e7et\u2019s disease. Br J Ophthalmol. 2001;85:1287.","journal-title":"Br J Ophthalmol"},{"key":"328_CR172","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1385\/CRIAI:29:3:295","volume":"29","author":"Z Tellier","year":"2005","unstructured":"Tellier Z. Intravenous immunoglobulin in eye involvement. Clin Rev Allergy Immunol. 2005;29:295\u2013306.","journal-title":"Clin Rev Allergy Immunol"},{"key":"328_CR173","doi-asserted-by":"crossref","unstructured":"Akman-Demir G, Serdaroglu P, Tas\u00e7i B. Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group. Brain. 1999;122(Pt 11):2171\u201382.","DOI":"10.1093\/brain\/122.11.2171"},{"key":"328_CR174","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/brain\/122.11.2183","volume":"122","author":"D Kidd","year":"1999","unstructured":"Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behcet\u2019s syndrome. Brain. 1999;122:2183\u201394.","journal-title":"Brain"},{"key":"328_CR175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s004150170242","volume":"248","author":"A Siva","year":"2001","unstructured":"Siva A, Kantarci OH, Saip S, et al. Behcet\u2019s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248:95\u2013103.","journal-title":"J Neurol"},{"key":"328_CR176","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet\u2019s syndrome: a 2-decade outcome survey of 387 patients followed at dedicated center. Medicine. 2003;82:60.","journal-title":"Medicine"},{"key":"328_CR177","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.42.3.614","volume":"42","author":"B Wechsler","year":"1992","unstructured":"Wechsler B, Vidailhet M, Piette JC, et al. Cerebral venous sinus thrombosis in Behcet\u2019s disease: long term follow up of 25 cases. Neurology. 1992;42:614\u20138.","journal-title":"Neurology"},{"key":"328_CR178","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s004150050205","volume":"245","author":"P Serdaroglou","year":"1998","unstructured":"Serdaroglou P. Behcet\u2019s disease and the nervous system. J Neurol. 1998;245:197\u2013205.","journal-title":"J Neurol"},{"key":"328_CR179","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00019052-200406000-00017","volume":"17","author":"A Siva","year":"2004","unstructured":"Siva A, Altintas A, Saip S. Behcet\u2019s disease and the nervous system. Curr Opin Neurol. 2004;17:347\u201357.","journal-title":"Curr Opin Neurol"},{"key":"328_CR180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s004150050317","volume":"246","author":"O Oktem-Tanor","year":"1999","unstructured":"Oktem-Tanor O, Baykan-Kurt B, G\u00fcrvit IH, Akman-Demir G, Serdaro\u011flu P. Neuropsychological follow up of 12 patients with neuro-Behcet\u2019s disease. J Neurol. 1999;246:113\u20139.","journal-title":"J Neurol"},{"key":"328_CR181","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1474-4422(09)70015-8","volume":"8","author":"A Al-Araji","year":"2009","unstructured":"Al-Araji A, Kidd DP. Neuro-Behcet\u2019s disease: epidemiology, clinical characteristics and management. Lancet Neurol. 2009;8:192\u2013204.","journal-title":"Lancet Neurol"},{"key":"328_CR182","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00415-009-0145-6","volume":"256","author":"A Siva","year":"2009","unstructured":"Siva A, Saip S. The spectrum of the nervous system in Neurobehcet\u2019s syndrome and its differential diagnosis. J Neurol. 2009;256:513\u201329.","journal-title":"J Neurol"},{"key":"328_CR183","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/B978-0-7020-4088-7.00110-3","volume":"121","author":"S Saip","year":"2014","unstructured":"Saip S, Akman-Demir G, Siva A. Neuro-Beh\u00e7et syndrome. Handb Clin Neurol. 2014;121:1703\u201323.","journal-title":"Handb Clin Neurol"},{"key":"328_CR184","doi-asserted-by":"crossref","unstructured":"Saip S, Siva A, Altintas A, et al. Headache in Behcet\u2019s syndrome. Headache 2005;45:911\u20139.","DOI":"10.1111\/j.1526-4610.2005.05160.x"},{"key":"328_CR185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000116342","volume":"26","author":"IJ Namer","year":"1987","unstructured":"Namer IJ, Karabudak R, Zileli T, Ruacan S, K\u00fc\u00e7\u00fckali T, Kansu E. Peripheral nervous system involvement in Behcet\u2019s disease. Eur Neurol. 1987;26:235\u201340.","journal-title":"Eur Neurol"},{"key":"328_CR186","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s004150200031","volume":"249","author":"A Lannuzel","year":"2002","unstructured":"Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D. Neurological manifestation in Behcet\u2019s disease in Carribean population: clinical and imaging findings. J Neurol. 2002;249:410\u20138.","journal-title":"J Neurol"},{"key":"328_CR187","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/ard.61.8.751","volume":"61","author":"H Sarui","year":"2002","unstructured":"Sarui H, Maruyama T, Ito I, et al. Necrotising miositi in Behcet\u2019s disease: characteristics on magnetic resonance imaging and a review of the literature. Ann Rheum Dis. 2002;61:751\u20132.","journal-title":"Ann Rheum Dis"},{"key":"328_CR188","doi-asserted-by":"crossref","unstructured":"Atasoy HT, Tunc TO, Unal AE, et al. Peripheral nervous system involvement in Behcet\u2019s disease in patients with Behcet\u2019s disease. Neurologist. 2007;13:225\u201330.","DOI":"10.1097\/NRL.0b013e31805778d1"},{"key":"328_CR189","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00019052-200406000-00017","volume":"17","author":"A Siva","year":"2004","unstructured":"Siva A, Altintas A, Saip S. Behcet\u2019s syndrome and the nervous system. Curr Opin Neurol. 2004;17:347\u201357.","journal-title":"Curr Opin Neurol"},{"key":"328_CR190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/clin.1996.4268","volume":"82","author":"S Hirohata","year":"1997","unstructured":"Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid IL6 in progressive neuro-behcet\u2019s syndrome. Clin Immunol Immunopathol. 1997;82:12\u20137.","journal-title":"Clin Immunol Immunopathol"},{"key":"328_CR191","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0022-510X(00)00403-2","volume":"179","author":"M Kawai","year":"2000","unstructured":"Kawai M, Hirohata S. Cerebrospinal fluid beta(2)-microglobulin in neuro-Behcet\u2019s syndrome. J Neurol Sci. 2000;179:132\u20139.","journal-title":"J Neurol Sci"},{"key":"328_CR192","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.24393","volume":"61","author":"D Saadoun","year":"2009","unstructured":"Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behcet\u2019s disease. Arthritis Rheum. 2009;61:518\u201326.","journal-title":"Arthritis Rheum"},{"key":"328_CR193","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s00415-009-5088-4","volume":"256","author":"N Yesilot","year":"2009","unstructured":"Yesilot N, Bahar S, Yilmazer S, et al. Cerebral venous thrombosis in Behcet\u2019s disease compared to those associated to other etiologies. J Neurol. 2009;256:1134\u201342.","journal-title":"J Neurol"},{"key":"328_CR194","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0248-8663(02)00621-5","volume":"23","author":"MH Houman","year":"2002","unstructured":"Houman MH, Hamzaoui-B\u2019Chir S, Ben GI, et al. Neurologic manifestations of Behcet\u2019s disease: analysis of a series of 27 patients. Rev Med Interne. 2002;23:592\u2013606.","journal-title":"Rev Med Interne"},{"key":"328_CR195","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF00588368","volume":"35","author":"S Bahar","year":"1993","unstructured":"Bahar S, Coban O, G\u00fcrvit IH, Akman-Demir G, G\u00f6kyi\u011fit A. Spontaneous dissection of the extracranial vertebral artery with spinal subarachnoid hemorrhage in a patient with Behcet\u2019s disease. Neuroradiology. 1993;35:352\u20134.","journal-title":"Neuroradiology"},{"key":"328_CR196","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1468-1331.2001.00300.x","volume":"8","author":"Y Krespi","year":"2001","unstructured":"Krespi Y, Akman-Demir G, Poyraz M, et al. Cerebral vasculitis and ischaemic stroke in Behcet\u2019s disease: report of one case and review of the literature. Eur J Neurol. 2001;8:719\u201322.","journal-title":"Eur J Neurol"},{"key":"328_CR197","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jnnp.73.3.343","volume":"73","author":"A Sagduyu","year":"2002","unstructured":"Sagduyu A, Sirin H, Oksel F, Turk T, Ozenc D. An unusual case of Behcet disease presenting with bilateral internal carotid artery occlusion. J Neurol Neurosurg Psychiatry. 2002;73:343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"328_CR198","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00234-003-0952-x","volume":"45","author":"O Kizilkilic","year":"2003","unstructured":"Kizilkilic O, Albayram S, Adaletli I, Ak H, Islak C, Kocer N. Endovascular treatment of Behcet\u2019s disease associated intracranial aneurysm: report of 2 cases and review of the literature. Neuroradiology. 2003;45:328\u201334.","journal-title":"Neuroradiology"},{"key":"328_CR199","first-page":"35","volume":"18","author":"EG Aktas","year":"2008","unstructured":"Aktas EG, Kaplan M, Ozveren MF. Basilar artery aneurysm associated with Behcet\u2019s disease: a case report. Turk Neurosurg. 2008;18:35\u20138.","journal-title":"Turk Neurosurg"},{"key":"328_CR200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2007.09.041","volume":"267","author":"S Hirohata","year":"2008","unstructured":"Hirohata S. Hystopathology of central nervous system lesions in Behcet\u2019s disease. J Neurol Sci. 2008;267:41\u20137.","journal-title":"J Neurol Sci"},{"key":"328_CR201","first-page":"249","volume":"15","author":"MG Hadfield","year":"1996","unstructured":"Hadfield MG, Aydin F, Lippman HR, Kubal WS, Sanders KM. Neurobehcet\u2019s disease. Clin Neuropathol. 1996;15:249\u201355.","journal-title":"Clin Neuropathol"},{"key":"328_CR202","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1440-1789.2006.00734.x","volume":"26","author":"Y Arai","year":"2006","unstructured":"Arai Y, Kohno S, Takahashi Y, Miyajima Y, Tsutusi Y. Autopsy case of neuro-Behcet\u2019s disease with multifocal neutrophilic perivascular inflammation. Neuropathology. 2006;26:579\u201385.","journal-title":"Neuropathology"},{"key":"328_CR203","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/0896-6273(93)90225-G","volume":"11","author":"JA Kessler","year":"1993","unstructured":"Kessler JA, Ludlam WH, Freidin MM, et al. Cytokine-induced programmed death of cultured sympathetic neurons. Neuron. 1993;11:1123\u201332.","journal-title":"Neuron"},{"key":"328_CR204","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1073\/pnas.94.4.1500","volume":"94","author":"CJ Heyser","year":"1997","unstructured":"Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing IL6 in the brain. Proct Natl Acad Sci. 1997;94:1500\u20135.","journal-title":"Proct Natl Acad Sci"},{"key":"328_CR205","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/14734220500199987","volume":"4","author":"DL Gruol","year":"2005","unstructured":"Gruol DL, Nelson TE. Purkinje neuron physiology is altered by the inflammatory factor IL6. Cerebellum. 2005;4:198\u2013205.","journal-title":"Cerebellum"},{"key":"328_CR206","first-page":"1015","volume":"20","author":"N Kocer","year":"1999","unstructured":"Kocer N, Islak C, Siva A, et al. CNS involvement in neurobehcet\u2019s syndrome: an MR study. AJNR. 1999;20:1015\u201324.","journal-title":"AJNR"},{"key":"328_CR207","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11940-000-0042-x","volume":"2","author":"A Siva","year":"2000","unstructured":"Siva A, Fresko I. Behcet\u2019s disease. Curr Treat Options Neurol. 2000;2:435\u201348.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"328_CR208","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s004150170242","volume":"248","author":"A Siva","year":"2001","unstructured":"Siva A, Kantarci OH, Saip S, et al. Beh\u00e7et\u2019s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248(2):95\u2013103.","journal-title":"J Neurol"},{"key":"328_CR209","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Behcet\u2019s disease. N Engl Med. 1999;341:1284\u201391.","journal-title":"N Engl Med"},{"issue":"7","key":"328_CR210","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/ncprheum0224","volume":"2","author":"S Hirohata","year":"2006","unstructured":"Hirohata S. Is the long-term use of systemic corticosteroids beneficial in the management of Beh\u00e7et\u2019s syndrome? Nat Clin Pract Rheumatol. 2006;2(7):358\u20139.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"328_CR211","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","volume":"106","author":"S Kotake","year":"1999","unstructured":"Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Bechet\u2019s disease receiving cyclosporine therapy. Opthalmology. 1999;106:586.","journal-title":"Opthalmology"},{"key":"328_CR212","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2169\/internalmedicine.44.149","volume":"44","author":"Y Mitsui","year":"2005","unstructured":"Mitsui Y, Mitsui M, Urakami R, Kihara M, Takahashi M, Kusunoki S. Behcet\u2019s disease presenting with neurological complication immediately after convention from conventional cyclosporine A to microemulsion formulation. Intern Med. 2005;44:149\u201352.","journal-title":"Intern Med"},{"key":"328_CR213","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"I Kotter","year":"2006","unstructured":"Kotter I, G\u00fcnaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behcet\u2019s disease under cyclosporin A than under other medications results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482\u20136.","journal-title":"Clin Rheumatol"},{"key":"328_CR214","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/0-306-48382-3_117","volume":"528","author":"H Kikuchi","year":"2003","unstructured":"Kikuchi H, Aramaki K, Hirohata S. Low dose of MTX for progressive neuro-Behcet\u2019s disease. A follow up study for 4 years. Adv Exp Med Biol. 2003;528:575\u20138.","journal-title":"Adv Exp Med Biol"},{"key":"328_CR215","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ard.62.3.280","volume":"62","author":"G Licata","year":"2003","unstructured":"Licata G, Pinto A, Tuttolomondo A, et al. Anti-TNF alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet\u2019s syndrome. Ann Rheum Dis. 2003;62:280\u20131.","journal-title":"Ann Rheum Dis"},{"key":"328_CR216","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/jnnp.2004.055434","volume":"76","author":"C Ribi","year":"2005","unstructured":"Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF alpha blockade in cyclophosphamide resistant neuro-behcet\u2019s disease. Neurol Neurosurg Psychiatry. 2005;76:1733\u20135.","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"328_CR217","first-page":"181","volume":"32","author":"H Sarwar","year":"2005","unstructured":"Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neurobehcet\u2019s disease with infliximab in patients with refractory disease. J Rheumatol. 2005;32:181\u20133.","journal-title":"J Rheumatol"},{"key":"328_CR218","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2006.056804","volume":"66","author":"K Fujikawa","year":"2007","unstructured":"Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neurobehcet\u2019s disease with infliximab: a case report to show its efficacy by MR imaging, transcranial magnetic stimulation and CK profile. Ann Rheum Dis. 2007;66:136\u20137.","journal-title":"Ann Rheum Dis"},{"key":"328_CR219","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","volume":"59","author":"N Pipitone","year":"2008","unstructured":"Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behcet\u2019s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285\u201390.","journal-title":"Arthritis Rheum"},{"key":"328_CR220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","volume":"272","author":"H Kikuchi","year":"2008","unstructured":"Kikuchi H, Aramaki K, Hirohata S. Effect of Infliximab in progressive Neuro-Behcet\u2019s syndrome. J Neurol Sci. 2008;272:99\u2013105.","journal-title":"J Neurol Sci"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0328-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-014-0328-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0328-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T00:08:41Z","timestamp":1566086921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-014-0328-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,2]]},"references-count":220,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1007\/s10238-014-0328-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,2]]}}}